Medlive Technology Co., Ltd. (HK:2192) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medlive Technology Co., Ltd. has extended its collaboration with M3 to provide digital market research and content services until the end of 2027. This agreement, originally set to expire in 2024, allows Medlive to continue offering specialized digital surveys and tailored content for medical professionals. The transaction is considered a continuing connected transaction under Hong Kong’s listing rules, requiring certain disclosures but not independent shareholder approval.
For further insights into HK:2192 stock, check out TipRanks’ Stock Analysis page.